Adalimumab: In Crohn's disease

BioDrugs

Volumn 21, Issue 2, 2007, Pages 125-132

  Plosker, Greg L ^a   Lyseng Williamson, Katherine A ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AMINOSALICYLIC ACID; CORTICOSTEROID; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; PLACEBO; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANKYLOSING SPONDYLITIS; ARTHRALGIA; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CROHN DISEASE; DEHYDRATION; DEMYELINATING DISEASE; DISEASE EXACERBATION; DRUG APPROVAL; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEVER; HEADACHE; HUMAN; INFECTION; INFLUENZA; INJECTION SITE BURNING; INJECTION SITE PAIN; INJECTION SITE REACTION; LYMPHOMA; NAUSEA; PATHOGENESIS; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RANDOMIZED CONTROLLED TRIAL; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SINGLE DRUG DOSE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

ANTIBODIES, MONOCLONAL; CROHN DISEASE; HUMANS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34247253049     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200721020-00007     Document Type: Review

References (39)

1. Shanahan F. Crohn's disease. Lancet 2002 Jan 5; 359 (9300): 62-9
2. Hanauer SB, Sandborn W. Management of Crohn's disease in adults. Am J Gastroenterol 2001 Mar; 96 (3): 635-43
3. Loftus EV Jr, Schoenfeld P, Sandborn WJ. The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America: a systematic review. Aliment Pharmacol Ther 2002 Jan; 16 (1): 51-60
4. Löwenberg M, Peppelenbosch M, Hommes D. Biological therapy in the management of recent-onset Crohn's disease: why, when and how? Drugs 2006; 66 (11): 1431-9
5. Sandborn WJ. Translating molecular biology into clinical practice: the role of TNF-α in Crohn's disease. Adv Studies Med 2005; 5 (9C): S852-9
6. Korzenik JR. Crohn's disease: future anti-tumor necrosis factor therapies beyond infliximab. Gastroenterol Clin North Am 2004; 33 (2): 285-301
7. Hanauer SB. Beyond molecular biology: improving quality of life in patients with Crohn's disease. Adv Studies Med 2005; 5 (9C): S860-7
8. Travis SPL, Stange EF, Lémann M, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut 2006; 55 Suppl. 1: i16-35
9. Humira® (adalimumab): US prescribing information. North Chicago (IL): Abbott Laboratories, 2007 Feb
10. Adalimumab (Humira®): summary of product characteristics. European Medicines Agency (EMEA), 2006 Nov 7
11. Humira® (adalimumab) receives FDA approval for treatment of Crohn's disease [media release]. Abbott Laboratories, 2007 Feb 27
12. Abbott Laboratories. Abbott submits US and EU regulatory applications seeking approval for Humira® (adalimumab) as a treatment for Crohn's disease [media release]. 2006 Sep 7
13. Shen C, Van Assche G, Rutgeerts P, et al. Caspase activation and apoptosis induction by adalimumab: demonstration in vitro and in vivo in a chimeric mouse model. Inflamm Bowel Dis 2006; 12 (1): 22-8
14. Shen C, Assche GV, Colpaert S, et al. Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment Pharmacol Ther 2005; 21 (3): 251-8
15. Anderson PJ. Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles. Semin Arthritis Rheum 2005 Jan; 34: 19-22
16. Breedveld FC. Therapeutic monoclonal antibodies. Lancet 2000; 355: 735-40
17. Paulson SK, Noertersheuser P, Pollack PF, et al. Pharmacokinetics of adalimumab from Classic, a randomized phase 3 trial for the induction of clinical remission in patients with Crohn's [abstract no. W1057]. Gastroenterology 2005 May 18; 128 (4 Suppl. 2): A-585. Plus poster presented at Digestive Disease Week; 2005 May 14-19; Chicago (IL)
18. Garimella TS, Peng JZ, Beck K, et al. Pharmacokinetics of adalimumab in a long-term investigation of the induction and maintenance of remission in patients with Crohn's disease (CLASSIC I and CLASSIC II) [abstract no. T1133]. Gastroenterology 2006 Apr 1; 130 (4 Suppl. 2): A-481. Plus poster presented at Digestive Disease Week; 2006 May 20-25; Los Angeles (CA)
19. Cvetković RS, Scott LJ. Adalimumab: a review of its use in adult patients with rheumatoid arthritis. Biodrugs 2006; 20 (5): 293-311
20. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006 Feb; 130 (2): 323-33
21. Colombel J-F, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007 Jan; 132 (1): 52-65
22. Rutgeerts P, Sandborn WJ, Enns R, et al. Adalimumab rapidly induces clinical response and remission in patients with moderate to severe Crohn's disease who had secondary failure to infliximab therapy: results of the GAIN Study [abstract no. OP-G-86]. Gut 2006 Oct; 55 Suppl. V: A20
23. Sandborn WJ, Hanauer SB, Rutgeerts PJ, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut. Epub 2007 Feb 13
24. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's disease ctivity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976 Mar; 70 (3): 439-44
25. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn's disease previously treated with infliximab: a randomized trial. Ann Intern Med. In press
26. Panaccione R, Hanauer SB, Fedorak R, et al. Concomitant immunosuppressive and adalimumab therapy in patients with Crohn's disease: 1-year results of the Classic II study [abstract no. T1124]. Gastroenterology 2006 Apr 1; 130 (4 Suppl. 2): A-479. Plus poster presented at Digestive Disease Week; 2006 May 20-25; Los Angeles (CA)
27. Rutgeerts PJ, Melilli LE, Li J, et al. Adalimumab maintains improvement in inflammatory bowel disease questionnaire scores over 1 year following the initial attainment of remission in patients with moderately to severely active Crohn's disease: Results of the classic II study [abstract no. T1125]. Gastroenterology 2006 Apr 1; 130 (4 Suppl. 2): A-479. Plus poster presented at Digestive Disease Week; 2006 May 20-25; Los Angeles (CA)
28. Hinojosa J, Gomollón F, García S, et al. Efficacy and safety of short-term adalimumab treatment in patients with active Crohn's disease who lost response or showed intolerance to infliximab: a prospective, open-label, multicentre trial. Aliment Pharmacol Ther 2007 Feb 15; 25 (4): 409-18
29. Sandborn WJ, Hanauer S, Loftus EV Jr, et al. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol 2004 Oct; 99 (10): 1984-9
30. Papadakis KA, Shaye OA, Vasiliauskas EA, et al. Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab. Am J Gastroenterol 2005 Jan; 100 (1): 75-9
31. Anwar M, O'Sullivan M, Ryan B, et al. An open label study of adalimumab in Crohn's disease patients with a loss of response to infliximab [abstract no. W1225]. Gastroenterology 2006 Apr 1; 130 (4 Suppl. 2): A-662
32. Mian S, Baron H. Adalimumab, a novel anti-tumor necrosis factor-alpha antibody in a child with refractory Crohn's disease. J Pediatr Gastroenterol Nutr 2005 Sep; 41 (3): 357-9
33. Coburn LA, Wise PE, Schwartz DA. The successful use of adalimumab to treat active Crohn's disease of an ileoanal pouch during pregnancy. Dig Dis Sci 2006 Nov; 51 (11): 2045-7
34. Vesga L, Terdiman JP, Mahadevan U. Adalimumab use in pregnancy [letter]. Gut 2005 Jun; 54 (6): 890
35. Mishkin DS, Van Deinse W, Becker JM, et al. Successful use of adalimumab (Humira) for Crohn's disease in pregnancy [letter]. Inflamm Bowel Dis 2006 Aug; 12 (8): 827-8
36. Lester M-A, Dit Dinard BM, Pagenault M, et al. Treatment of Crohn's disease by adalimumab anti-TNF monoclonal antibody in an infliximab-allergic patient [abstract no. PT-186]. Pharm World Sci 2005 Oct; 27 (5): A98
37. Deslandres C, Faure C, Dirks MH, et al. Open label experience in adalimumab in pediatric Crohn's disease patients who lost response or were intolerant to infliximab [abstract no. W1199]. Gastroenterology 2006 Apr 1; 130 (4 Suppl. 2): A-656
38. Youdim A, Vasiliauskas EA, Targan SR, et al. A pilot study of adalimumab in infliximab-allergic patients. Inflamm Bowel Dis 2004 Jul; 10 (4): 333-8
39. Burmester GR, Panaccione R, Kent JD, et al. Adalimumab safety in Crohn's disease and rheumatoid arthritis clinical trials, reduced mortaility in rheumatoid arthritis [abstract no. 1160]. Am J Gastroenterol 2006 Sep; 101 Suppl. (9): 452-3